The Institute for Biomedical Research and Innovation of I-faute-Normandie (IRIB), established in 2012 federative structure, is a member of a research network of the GRR Chemistry-Biologie-Health. Since its inception, he has contributed significantly to the structuring of biomedical research at the University of Rouen-Normandie by coordinating, in conjunction with the CHU — Hospitals of Rouen, the activity of the Founding Units around a common unifying theme: the development of a high-level biomedical research focused on the understanding of the physiopathology of diseases and the development of new diagnostic and therapeutic tools.The IIB is currently consolidating the competences of 19 Research Units of the University of Rouen, all labelled (6 Mixed Units of Inserm Research — University of Rouen, a Multi-site Inserm Unit, an Inserm Team — Region — University of Rouen, 2 CNRS Joint Research Units — University of Rouen, 8 Hospital Teams from the University of Rouen and a CIC — Inserm — CHU de Rouen. In order to carry out the research programmes, the IRIB has set up an important technical platform consisting, inter alia, of the Centre d’Investigation Clinique (CIC), the Regional Platform for Research in Cellular Imagery of Normandy (PRIMACEN), the Instrumental Platform in Separative and Analytical Sciences of Rouen (Pissaro), the Platform for Behavioural Analysis (SCAC) certified by the GIS IBiSA and of 5 common high-performance services genomic analysis, small animal imaging (pictur), flow and cell sorting cytometry (CyFlow), oxidative stress assessment (BOSS) and the Centre for Innovation and Engineering in Organic Chemistry and Analysis (C21OrgA) as well as two pooled central animal plants located respectively at the Faculty of Science and the Faculty of Medicine-P Pharmacy, which are widely open to the scientific community but also to industry.Translational research or transfer research has emerged over the past twenty years as an expression of an essential need for the promises of fundamental research to be rapidly translated into improved health of individuals and populations and better patient management. Translational research is therefore based on bidirectional exchanges between exploratory researchers, clinicians and epidemiologists to design and validate new preventive, diagnostic, prognostic or therapeutic strategies.In the context of France’s backlog in translational research, the strategic scientific objective of the IIB is to become a reference centre in this field, building on the skills and synergies of the 19 teams of chemists. physicochemists, biochemists, pharmacologists and clinicians, in a continuum ranging from the most fundamental research to clinical applications, in coherence with the Chemistry-Biology-Health technopole.Thus, within the IIB, this translational research focuses in particular on public health problems both at regional and national level, and by way of example, the IRIB teams have developed new diagnostic markers and therapeutic strategies in the areas of Alzheimer’s disease, neonatal disability, cancer, cardiovascular disease, digestive diseases and nutrition, and these advances have been disseminated nationally and internationally.In order to achieve this ambitious goal, the IIB wants to continue to promote Translational Actions in Chemistry-Biology-Health (PACT-CBS) by strengthening the resources (technical and human) of the IIB’s technical trays. so that they can respond positively to the growing needs of cross-cutting multidisciplinary projects (13 projects) and thesis (6 projects).
